ERBB2 and non-small cell lung carcinoma: Within the Drug Rediscovery Protocol (DRUP) framework, a study sought to evaluate the efficacy of a combination therapy involving trastuzumab and pertuzumab in patients with NSCLC harboring HER2 exon 20 mutations (165).